Novel therapies in genitourinary cancer: An update

David Chu; Shenhong Wu

doi:10.1186/1756-8722-1-11

Novel therapies in genitourinary cancer: An update

David Chu
, Shenhong Wu

Medical Oncology

Stony Brook University

Research output: Contribution to journal › Review article › peer-review

3 Scopus citations

Abstract

In recent years, new treatment for renal cell carcinoma (RCC) has been a spotlight in the field of cancer therapeutics. With several emerging agents branded as 'targeted therapy' now available, both medical oncologists and urologists are progressively more hopeful for better outcomes. The new remedies may provide patients with improved survival and at the same time less toxicity when compared to traditional cytotoxic agents. This article will center on current and emerging treatment strategies for advanced RCC and other GU malignancies with updates from 2008 annual ASCO meeting.

Original language	English
Article number	11
Journal	Journal of Hematology and Oncology
Volume	1
Issue number	1
DOIs	https://doi.org/10.1186/1756-8722-1-11
State	Published - 2008

Access to Document

10.1186/1756-8722-1-11

Cite this

@article{fb28a144fbe04ad6b7f7ec353086181c,

title = "Novel therapies in genitourinary cancer: An update",

abstract = "In recent years, new treatment for renal cell carcinoma (RCC) has been a spotlight in the field of cancer therapeutics. With several emerging agents branded as 'targeted therapy' now available, both medical oncologists and urologists are progressively more hopeful for better outcomes. The new remedies may provide patients with improved survival and at the same time less toxicity when compared to traditional cytotoxic agents. This article will center on current and emerging treatment strategies for advanced RCC and other GU malignancies with updates from 2008 annual ASCO meeting.",

author = "David Chu and Shenhong Wu",

year = "2008",

doi = "10.1186/1756-8722-1-11",

language = "English",

volume = "1",

journal = "Journal of Hematology and Oncology",

issn = "1756-8722",

number = "1",

}

TY - JOUR

T1 - Novel therapies in genitourinary cancer

T2 - An update

AU - Chu, David

AU - Wu, Shenhong

PY - 2008

Y1 - 2008

N2 - In recent years, new treatment for renal cell carcinoma (RCC) has been a spotlight in the field of cancer therapeutics. With several emerging agents branded as 'targeted therapy' now available, both medical oncologists and urologists are progressively more hopeful for better outcomes. The new remedies may provide patients with improved survival and at the same time less toxicity when compared to traditional cytotoxic agents. This article will center on current and emerging treatment strategies for advanced RCC and other GU malignancies with updates from 2008 annual ASCO meeting.

AB - In recent years, new treatment for renal cell carcinoma (RCC) has been a spotlight in the field of cancer therapeutics. With several emerging agents branded as 'targeted therapy' now available, both medical oncologists and urologists are progressively more hopeful for better outcomes. The new remedies may provide patients with improved survival and at the same time less toxicity when compared to traditional cytotoxic agents. This article will center on current and emerging treatment strategies for advanced RCC and other GU malignancies with updates from 2008 annual ASCO meeting.

UR - https://www.scopus.com/pages/publications/66949132663

U2 - 10.1186/1756-8722-1-11

DO - 10.1186/1756-8722-1-11

M3 - Review article

C2 - 18694493

AN - SCOPUS:66949132663

SN - 1756-8722

VL - 1

JO - Journal of Hematology and Oncology

JF - Journal of Hematology and Oncology

IS - 1

M1 - 11

ER -

Novel therapies in genitourinary cancer: An update

Abstract

Access to Document

Other files and links

Fingerprint

Cite this